CLDN18 and gastric cancer: Among other CLDN18.2-targeting ADCs with an MMAE payload, phase I studies of ATG-022 (NCT05718895), EO-3021 (NCT05009966) and JS107 (NCT05502393) revealed ORRs of 42% (5/12) in gastric cancer patients (Ma et al., 2025), 38% (8/21) in gastric or pancreatic cancer patients (Wang Y. et al., 2023) and 35% (8/23) in CLDN18.2-high G/GEJAC patients (Xu R. H. et al., 2025), respectively, whereas a phase I/II clinical trial of ciletatug vedotin (NCT05205850) revealed an ORR of 47% (8/17) in CLDN18.2-positive G/GEJAC patients (Liu T et al., 2024).